WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma

Journal of Clinical Pathology

Volumn 67, Issue 7, 2014, Pages 556-561

  Rauscher, Julian ^a   Beschorner, Rudi ^a   Gierke, Midea ^a   Bisdas, Sotirios ^a   Braun, Christian ^a   Ebner, Florian H ^a   Schittenhelm, Jens ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TUMOR MARKER; WT1 PROTEIN;

AGE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; NEUROPATHOLOGY; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

BRAIN; NEUROPATHOLOGY; ONCOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DATABASES, GENETIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; FEMALE; GENES, WILMS TUMOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; OLIGODENDROGLIOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; WT1 PROTEINS; YOUNG ADULT;

EID: 84904359672     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-202114     Document Type: Article

References (38)

1. Pritchard-Jones K. The Wilms tumour gene, WT1, in normal and abnormal nephrogenesis. Pediatr Nephrol 1999;13:620-5. (Pubitemid 29403485)
2. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumour locus. Cell 1990;60:509-20.
3. Madden SL, Cook DM, Morris JF, et al. Transcriptional repression mediated by the WT1 Wilms tumour gene product. Science 1991;253:1550-3. (Pubitemid 21917311)
4. Menke AL, van der Eb AJ, Jochemsen AG. The Wilms ' tumour 1 gene: oncogene or tumour suppressor gene?. Int Rev Cytol 1998;181:151-212. (Pubitemid 28151877)
5. Bansal H, Seifert T, Bachier C, et al. The transcription factor Wilms tumour 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL by regulating the antiapoptotic protein Bcl-xL. J Biol Chem 2012;287:32875-80.
6. Zapata-Benavides P, Manilla-Muñoz E, Zamora-Avila DE, et al. WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells. Oncol Lett 2012;3:751-5.
7. Menssen HD, Bertelmann E, Bartelt S, et al. Wilms' tumour gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumour specimens. J Cancer Res Clin Oncol 2000;126:226-32. (Pubitemid 30183026)
8. Oji Y, Suzuki T, Nakano Y, et al. Overexpression of the Wilms' tumour gene W T1 in primary astrocytic tumours. Cancer Sci 2004;95:822-7. (Pubitemid 39545589)
9. Nakahara Y, Okamoto H, Mineta T, et al. Expression of the Wilms' tumour gene product WT1 in glioblastomas and medulloblastomas. Brain Tumour Pathol 2004;21:113-16. (Pubitemid 40187985)
10. Hashiba T, Izumoto S, Kagawa N, et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumours. Neurol Med Chir 2007;47:165-70. (Pubitemid 46663616)
11. Rushing EJ, Sandberg GD, Horkayne-Szakaly I. High-grade astrocytomas show increased Nestin and Wilms's tumour gene (WT1) protein expression. Int J Surg Pathol 2010;18:255-9.
12. Schittenhelm J, Mittelbronn M, Nguyen TD, et al. WT1 expression distinguishes astrocytic tumour cells from normal and reactive astrocytes. Brain Pathol 2008;18:344-53. (Pubitemid 351782842)
13. Clark AJ, Dos Santos WG, McCready J, et al . Wilms tumour 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg 2007;107:586-92. (Pubitemid 47451043)
14. Bourne TD, Elias WJ, Lopes MB, et al. WT1 is not a reliable marker to distinguish reactive from neoplastic astrocyte populations in the central nervous system. Brain Pathol 2010;20:1090-5.
15. Capper D, Sahm F, Hartmann C, et al. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010;34:1199-204.
16. Asemissen AM, Keilholz U, Tenzer S, et al. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 2006;12:7476-82. (Pubitemid 46095423)
17. Anguille S, Fujiki F, Smits EL, et al. Identi fication of a Wilms' tumour 1 (WT1)-derived immunogenic CD4(+) T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes. Leukemia 2013;27:748-50.
18. Morita S, Oka Y, Tsuboi A, et al. A phase I/II trial of a WT1 (Wilms' tumour gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006;36:231-6. (Pubitemid 43997323)
19. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumour 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008;108:963-71. (Pubitemid 351656845)
20. Chiba Y, Kinoshita M, Okita Y, et al. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma. J Neurosurg 2012;116:835-42.
21. Schittenhelm J, Beschorner R, Simon P, et al. Diagnostic value of WT1 in neuroepithelial tumours. Neuropathol Appl Neurobiol 2009;35:69-81.
22. Schittenhelm J, Thiericke J, Nagel C, et al. WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy. Cancer Biomark 2010;7:73-7.
23. Louis DN, Ohgaki H, Wiestler OD, et al. Pathology & Genetics: WHO classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer Press, 2007.
24. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol 1994;4:229-37. (Pubitemid 24261929)
25. Yamada T, Kawamata T, Walker DG, et al. Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol 1992;84:157-62.
26. Blümcke I, Müller S, Buslei R, et al. Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumours. Acta Neuropathol 2004;108:89-96. (Pubitemid 39136293)
27. Blümcke I, Becker AJ, Normann S, et al. Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol 2001;60:984-93. (Pubitemid 32924124)
28. Marie Y, Sanson M, Mokhtari K, et al. OLIG2 as a speci fic marker of oligodendroglial tumour cells. Lancet 2001;358:298-300. (Pubitemid 32738972)
29. Kuhlmann T, Gutenberg A, Schulten HJ, et al. Nogo-a expression in glial CNS tumours: a tool to differentiate between oligodendrogliomas and other gliomas? Am J Surg Pathol 2008;32:1444-53.
30. Li A, Walling J, Ahn S, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009;69:2091-9.
31. Clark AJ, Chan DC, Chen MY, et al. Down-regulation of Wilms' tumour 1 expression in glioblastoma cells increases radiosensitivity independently of p53. J Neurooncol 2007;83:163-72. (Pubitemid 46784989)
32. Chiba Y, Hashimoto N, Tsuboi A, et al. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumour Pathol 2010;27:29-34.
33. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9. (Pubitemid 24328100)
34. Santamaría C, Ramos F, Puig N, et al. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. Ann Hematol 2012;91:1887-95.
35. Coosemans A, Van Calster B, Verbist G, et al. Wilms tumour gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma. Int J Gynecol Cancer 2011;21:3028.
36. Qi XW, Zhang F, Yang XH, et al. High Wilms' tumour 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer. Oncol Rep 2012;28:1231-6.
37. Dohi S, Ohno S, Ohno Y, et al. Correlation between WT1 expression and cell proliferation in endometrial cancer. Anticancer Res 2009;29:4887-9.
38. Ho PA, Alonzo TA, Gerbing RB, et al. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: Report from the Children's Oncology Group. Pediatr Blood Cancer 2014;61:81-8.